ALK-Abelló A/S
OTC: AKBLF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Peter Halling
- Employees
- 2,736
- Headquarters
- Horsholm, Denmark
- IPO year
- 2009
- Market cap
- $8.2B
- Website
- https://www.alk.net
Loading AKBLF…
Loading profile data…Frequently asked questions about AKBLF
What does ALK-Abelló A/S (AKBLF) do?
Established in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló A/S is a global pharmaceutical enterprise specializing in allergy treatment. The company provides a comprehensive range of allergy solutions to markets across Europe, North America, and other international regions. These offerings include immunotherapy products delivered thro...
Where does AKBLF trade?
ALK-Abelló A/S (AKBLF) trades on the Other OTC.
What sector is AKBLF in?
ALK-Abelló A/S (AKBLF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ALK-Abelló A/S?
Peter Halling is the chief executive officer of ALK-Abelló A/S (AKBLF).
Where is ALK-Abelló A/S headquartered?
ALK-Abelló A/S is headquartered in Denmark.
Does AKBLF pay a dividend?
Yes — ALK-Abelló A/S (AKBLF) paid a trailing twelve-month dividend of USD 0.25 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did AKBLF go public?
ALK-Abelló A/S (AKBLF) completed its initial public offering in 2009.